Clinical Scorecard: The Role of Microbiota, Mucus, and Therapeutic Modulators in the Pathogenesis of Infections in Cystic Fibrosis During the Era of CFTR Modulator Treatments

At a Glance

Key Highlights

• CF airway infections are polymicrobial, often dominated by pathogens such as Pseudomonas aeruginosa, Staphylococcus aureus, Burkholderia, Stenotrophomonas, Achromobacter, and nontuberculous mycobacteria.
• Highly effective CFTR modulators (e.g., elexacaftor/tezacaftor/ivacaftor) improve airway hydration and mucociliary clearance, reducing pathogen acquisition and density but do not fully eradicate chronic infections.
• Chronic infection with CF pathogens correlates with accelerated lung function decline, increased pulmonary exacerbations, and higher mortality risk.

Guideline-Based Recommendations

Diagnosis

• Use CF-specific selective culture media on respiratory samples (oropharyngeal swabs, sputum, bronchoalveolar lavage) for pathogen identification.
• Employ culture-independent DNA sequencing methods (16S amplicon, metagenomic sequencing) to characterize polymicrobial airway communities.
• Monitor age-related infection patterns to guide clinical management.

Management

• Implement airway clearance techniques and antibiotic therapies targeting dominant CF pathogens.
• Use CFTR modulator therapies (e.g., ivacaftor, elexacaftor/tezacaftor/ivacaftor) to restore CFTR function and improve mucociliary clearance.
• Apply long-term inhaled antibiotic suppression for chronic Pseudomonas aeruginosa infection due to difficulty in eradication.

Monitoring & Follow-up

• Longitudinal tracking of respiratory infections via registries such as the CF Foundation Patient Registry.
• Regular assessment of lung function (FEV1) and infection status to evaluate disease progression and treatment response.
• Monitor microbial diversity and pathogen dominance as markers of lung disease severity.

Risks

• Chronic infection with CF pathogens leads to accelerated lung function decline and increased mortality.
• Antibiotic resistance complicates treatment regimens for pathogens like MRSA, Burkholderia, and nontuberculous mycobacteria.
• Incomplete eradication of pathogens despite CFTR modulator therapy necessitates ongoing infection management.

Patient & Prescribing Data

People with cystic fibrosis, including children and adults with established airway infections

CFTR modulators improve airway hydration and reduce pathogen density but most patients with established infections remain chronically infected; long-term effects on infection dynamics and clinical outcomes require further study.

Clinical Best Practices

• Early identification and longitudinal monitoring of CF pathogens to guide targeted antibiotic therapy.
• Incorporation of CFTR modulator therapy to improve mucociliary clearance and reduce infection burden.
• Use of both culture-based and molecular diagnostic methods for comprehensive airway microbiome assessment.
• Continued airway clearance and infection suppression strategies despite CFTR modulator treatment.
• Regular lung function monitoring to detect disease progression and adjust management accordingly.

References

• CF Foundation Patient Registry
• CFTR Modulator Therapies Overview
• Role of Pseudomonas aeruginosa in CF Lung Disease